Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 681

1.

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Astorgues-Xerri L, Vázquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, Bekradda M, Coudé MM, Dombret H, Gardin C, Lokiec F, Raymond E, Noel K, Cvitkovic E, Herait P, Bertoni F, Riveiro ME.

Leuk Lymphoma. 2019 Jun 17:1-4. doi: 10.1080/10428194.2019.1617860. [Epub ahead of print] No abstract available.

PMID:
31204545
2.

The ETS inhibitors YK-4-279 and TK-216 are novel anti-lymphoma agents.

Spriano F, Chung EYL, Gaudio E, Tarantelli C, Cascione L, Napoli S, Jessen K, Carrassa L, Priebe V, Sartori G, Graham G, Selvanathan SP, Cavalli A, Rinaldi A, Kwee I, Testoni M, Genini D, Ye BH, Zucca E, Stathis A, Lannutti B, Toretsky JA, Bertoni F.

Clin Cancer Res. 2019 Jun 10. pii: clincanres.2718.2018. doi: 10.1158/1078-0432.CCR-18-2718. [Epub ahead of print]

PMID:
31182435
3.

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax.

Tarantelli C, Gaudio E, Hillmann P, Spriano F, Sartori G, Aresu L, Cascione L, Rageot D, Kwee I, Beaufils F, Zucca E, Stathis A, Wymann MP, Cmiljanovic V, Fabbro D, Bertoni F.

Cancers (Basel). 2019 Jun 4;11(6). pii: E775. doi: 10.3390/cancers11060775.

4.

Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies.

Bertoni F, Stathis A.

Curr Opin Hematol. 2019 Jul;26(4):273-280. doi: 10.1097/MOH.0000000000000519.

PMID:
31116107
5.

DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas.

Restelli V, Lupi M, Chilà R, Vagni M, Tarantelli C, Spriano F, Gaudio E, Bertoni F, Damia G, Carrassa L.

Mol Cancer Ther. 2019 May 7. doi: 10.1158/1535-7163.MCT-18-0919. [Epub ahead of print]

PMID:
31064869
6.

Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified.

Laginestra MA, Cascione L, Motta G, Fuligni F, Agostinelli C, Rossi M, Sapienza MR, Righi S, Broccoli A, Indio V, Melle F, Tabanelli V, Calleri A, Novero D, Facchetti F, Inghirami G, Sabattini E, Bertoni F, Pileri SA.

Mod Pathol. 2019 Apr 25. doi: 10.1038/s41379-019-0279-8. [Epub ahead of print]

PMID:
31028364
7.

Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses.

Cascione L, Rinaldi A, Bruscaggin A, Tarantelli C, Arribas AJ, Kwee I, Pecciarini L, Mensah AA, Spina V, Chung EYL, Terzi di Bergamo L, Dirnhofer S, Tzankov A, Miranda RN, Young KH, Traverse-Glehen A, Gaidano G, Swerdlow SH, Gascoyne R, Rabadan R, Ponzoni M, Bhagat G, Rossi D, Zucca E, Bertoni F.

Haematologica. 2019 Apr 24. pii: haematol.2018.214957. doi: 10.3324/haematol.2018.214957. [Epub ahead of print]

8.

Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq.

Giannuzzi D, Marconato L, Cascione L, Comazzi S, Elgendy R, Pegolo S, Cecchinato A, Bertoni F, Aresu L, Ferraresso S.

PLoS One. 2019 Apr 24;14(4):e0215154. doi: 10.1371/journal.pone.0215154. eCollection 2019.

9.

Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica.

Banna GL, Nicolai N, Palmieri G, Ottaviano M, Balzarini L, Barone D, Basso U, Bavila A, Bertoni F, Calliada F, Cai T, Carrafiello G, Condello C, Da Pozzo L, Di Nardo D, Fornarini G, Prayer Galetti T, Garolla A, Giannatempo P, Guerra L, La Spina S, Malatino L, Marchiano' A, Monti M, Morbiato FF, Morelli F, Nole' F, Palazzi S, Procopio G, Rosti G, Sacco C, Salvetti A, Salvioni R, Sava T, Secondino S, Serpentini S, Spreafico C, Tavolini IM, Valcamonico F, Verri E, Zucali P, De Giorgi U.

Crit Rev Oncol Hematol. 2019 May;137:154-164. doi: 10.1016/j.critrevonc.2019.03.006. Epub 2019 Mar 20. Review.

PMID:
31014511
10.

Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.

Sasi BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzynska B, Stachura J, Zerrouqi A, Bobrowicz M, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, Efremov DG.

Leukemia. 2019 Mar 14. doi: 10.1038/s41375-019-0442-8. [Epub ahead of print]

PMID:
30872780
11.

The mesopelagic anoxic Black Sea as an unexpected habitat for Synechococcus challenges our understanding of global "deep red fluorescence".

Callieri C, Slabakova V, Dzhembekova N, Slabakova N, Peneva E, Cabello-Yeves PJ, Di Cesare A, Eckert EM, Bertoni R, Corno G, Salcher MM, Kamburska L, Bertoni F, Moncheva S.

ISME J. 2019 Feb 28. doi: 10.1038/s41396-019-0378-z. [Epub ahead of print]

PMID:
30820035
12.

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma.

González-Rincón J, Méndez M, Gómez S, García JF, Martín P, Bellas C, Pedrosa L, Rodríguez-Pinilla SM, Camacho FI, Quero C, Pérez-Callejo D, Rueda A, Llanos M, Gómez-Codina J, Piris MA, Montes-Moreno S, Bárcena C, Rodríguez-Abreu D, Menárguez J, de la Cruz-Merino L, Monsalvo S, Parejo C, Royuela A, Kwee I, Cascione L, Arribas A, Bertoni F, Mollejo M, Provencio M, Sánchez-Beato M.

PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.

13.

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J.

Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19.

PMID:
30782609
14.

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity than SAR3419 in CD19-positive lymphoma and leukemia models.

Hicks SW, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas AJ, Spriano F, Bordone R, Cascione L, Lai KC, Qiu Q, Taborelli M, Rossi D, Stüssi G, Zucca E, Stathis A, Sloss CM, Bertoni F.

Haematologica. 2019 Feb 7. pii: haematol.2018.211011. doi: 10.3324/haematol.2018.211011. [Epub ahead of print]

15.

Impact of Surgical Approach on Patient-Reported Outcomes after Radical Prostatectomy: A Propensity Score-Weighted Analysis from a Multicenter, Prospective, Observational Study (The Pros-IT CNR Study).

Antonelli A, Palumbo C, Noale M, Porreca A, Maggi S, Simeone C, Bassi P, Bertoni F, Bracarda S, Buglione M, Conti GN, Corvò R, Gacci M, Mirone V, Montironi R, Triggiani L, Tubaro A, Artibani W; Pros-IT CNR study group.

Urol Int. 2019 Feb 7:1-11. doi: 10.1159/000496980. [Epub ahead of print]

PMID:
30731456
16.

Genome-wide promoter methylation of hairy cell leukemia.

Arribas AJ, Rinaldi A, Chiodin G, Kwee I, Mensah AA, Cascione L, Rossi D, Kanduri M, Rosenquist R, Zucca E, Johnson PW, Gaidano G, Oakes CC, Bertoni F, Forconi F.

Blood Adv. 2019 Feb 12;3(3):384-396. doi: 10.1182/bloodadvances.2018024059.

17.

The BTK inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents.

Tarantelli C, Zhang L, Curti E, Gaudio E, Spriano F, Priebe V, Cascione L, Arribas AJ, Zucca E, Rossi D, Stathis A, Bertoni F.

Haematologica. 2019 Jan 24. pii: haematol.2018.214759. doi: 10.3324/haematol.2018.214759. [Epub ahead of print]

18.

In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas.

Tarantelli C, Gaudio E, Cascione L, Stathis A, Zucca E, Bertoni F.

Br J Haematol. 2018 Dec 19. doi: 10.1111/bjh.15727. [Epub ahead of print] No abstract available.

PMID:
30569468
19.

New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease.

Aresu L, Ferraresso S, Marconato L, Cascione L, Napoli S, Gaudio E, Kwee I, Tarantelli C, Testa A, Maniaci C, Ciulli A, Hillmann P, Bohnacker T, Wymann MP, Comazzi S, Milan M, Riondato F, Rovere GD, Giantin M, Giannuzzi D, Bertoni F.

Haematologica. 2019 Jun;104(6):e256-e259. doi: 10.3324/haematol.2018.207027. Epub 2018 Dec 13. No abstract available.

20.

Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach.

Da Ros S, Aresu L, Ferraresso S, Zorzan E, Gaudio E, Bertoni F, Dacasto M, Giantin M.

PLoS One. 2018 Dec 11;13(12):e0208709. doi: 10.1371/journal.pone.0208709. eCollection 2018.

21.

Correction to: cuRnet: an R package for graph traversing on GPU.

Bonnici V, Busato F, Aldegheri S, Akhmedov M, Cascione L, Carmena AA, Bertoni F, Bombieri N, Kwee I, Giugno R.

BMC Bioinformatics. 2018 Nov 27;19(1):456. doi: 10.1186/s12859-018-2484-8.

22.

IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies.

Bergaggio E, Riganti C, Garaffo G, Vitale N, Mereu E, Bandini C, Pellegrino E, Pullano V, Omedè P, Todoerti K, Cascione L, Audrito V, Riccio A, Rossi A, Bertoni F, Deaglio S, Neri A, Palumbo A, Piva R.

Blood. 2019 Jan 10;133(2):156-167. doi: 10.1182/blood-2018-05-850826. Epub 2018 Nov 19.

PMID:
30455381
23.

The involvement of microRNA in the pathogenesis of Richter syndrome.

Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson PA, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA.

Haematologica. 2019 May;104(5):1004-1015. doi: 10.3324/haematol.2018.203828. Epub 2018 Nov 8.

24.

cuRnet: an R package for graph traversing on GPU.

Bonnici V, Busato F, Aldegheri S, Akhmedov M, Cascione L, Carmena AA, Bertoni F, Bombieri N, Kwee I, Giugno R.

BMC Bioinformatics. 2018 Oct 15;19(Suppl 10):356. doi: 10.1186/s12859-018-2310-3. Erratum in: BMC Bioinformatics. 2018 Nov 27;19(1):456.

25.

BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.

Tarantelli C, Bernasconi E, Gaudio E, Cascione L, Restelli V, Arribas AJ, Spriano F, Rinaldi A, Mensah AA, Kwee I, Ponzoni M M.D, Zucca E, Carrassa L, Riveiro ME, Rezai K, Stathis A, Cvitkovic E, Bertoni F.

ESMO Open. 2018 Sep 26;3(6):e000387. doi: 10.1136/esmoopen-2018-000387. eCollection 2018.

26.

T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways.

Paduano F, Gaudio E, Mensah AA, Pinton S, Bertoni F, Trapasso F.

Front Oncol. 2018 Aug 13;8:317. doi: 10.3389/fonc.2018.00317. eCollection 2018.

27.

Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Conconi A, Zucca E, Margiotta-Casaluci G, Darling K, Hasse B, Battegay M, Staehelin C, Novak U, Schmid P, Scherrer A, Dirnhofer S, Kwee I, Nassi L, Cavalli F, Gaidano G, Bertoni F, Bernasconi E; Swiss HIV Cohort study (SHCS).

Hematol Oncol. 2018 Dec;36(5):757-764. doi: 10.1002/hon.2536. Epub 2018 Aug 16.

PMID:
30113708
28.

Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, de Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Sep;50(9):1343. doi: 10.1038/s41588-018-0181-1.

PMID:
30089860
29.

Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.

Mensah AA, Cascione L, Gaudio E, Tarantelli C, Bomben R, Bernasconi E, Zito D, Lampis A, Hahne JC, Rinaldi A, Stathis A, Zucca E, Kwee I, Gattei V, Valeri N, Riveiro ME, Bertoni F.

Haematologica. 2018 Dec;103(12):2049-2058. doi: 10.3324/haematol.2018.191684. Epub 2018 Aug 3.

30.

Application of coumarin dyes for organic photoredox catalysis.

Gualandi A, Rodeghiero G, Della Rocca E, Bertoni F, Marchini M, Perciaccante R, Jansen TP, Ceroni P, Cozzi PG.

Chem Commun (Camb). 2018 Sep 6;54(72):10044-10047. doi: 10.1039/c8cc04048f.

PMID:
30039815
31.

GUROPA survey: genito-urinary radiation oncology prescription attitudes.

Fersino S, Arcangeli S, Jereczek-Fossa BA, D'Angelillo R, Bertoni F, D'Agostino GR, Triggiani L, Corvò R, Magrini SM, Alongi F; on the behalf of AIRO.

Radiol Med. 2018 Nov;123(11):879-884. doi: 10.1007/s11547-018-0918-z. Epub 2018 Jul 13.

PMID:
30006764
32.

Pixantrone: novel mode of action and clinical readouts.

Minotti G, Han H, Cattan V, Egorov A, Bertoni F.

Expert Rev Hematol. 2018 Jul;11(7):587-596. doi: 10.1080/17474086.2018.1476848. Epub 2018 Jun 18. Review.

PMID:
29912583
33.

Disease-specific and general health-related quality of life in newly diagnosed prostate cancer patients: the Pros-IT CNR study.

Porreca A, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group.

Health Qual Life Outcomes. 2018 Jun 13;16(1):122. doi: 10.1186/s12955-018-0952-5.

34.

Recent advances in understanding the biology of marginal zone lymphoma.

Bertoni F, Rossi D, Zucca E.

F1000Res. 2018 Mar 28;7:406. doi: 10.12688/f1000research.13826.1. eCollection 2018. Review.

35.

Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma.

Spriano F, Chung EY, Panini N, Cascione L, Rinaldi A, Erba E, Stathis A, D'Incalci M, Bertoni F, Gatta R.

Br J Haematol. 2019 Mar;184(6):1022-1025. doi: 10.1111/bjh.15212. Epub 2018 Apr 2. No abstract available.

PMID:
29611184
36.

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias.

Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucca E, Ghielmini M, Cortelezzi A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A.

Haematologica. 2018 Jun;103(6):e245-e248. doi: 10.3324/haematol.2017.184358. Epub 2018 Feb 22. No abstract available.

37.

Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides.

Bergmann TJ, Fregno I, Fumagalli F, Rinaldi A, Bertoni F, Boersema PJ, Picotti P, Molinari M.

J Biol Chem. 2018 Apr 13;293(15):5600-5612. doi: 10.1074/jbc.RA117.001484. Epub 2018 Feb 16.

38.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

Spina V, Bruscaggin A, Cuccaro A, Martini M, Di Trani M, Forestieri G, Manzoni M, Condoluci A, Arribas A, Terzi-Di-Bergamo L, Locatelli SL, Cupelli E, Ceriani L, Moccia AA, Stathis A, Nassi L, Deambrogi C, Diop F, Guidetti F, Cocomazzi A, Annunziata S, Rufini V, Giordano A, Neri A, Boldorini R, Gerber B, Bertoni F, Ghielmini M, Stüssi G, Santoro A, Cavalli F, Zucca E, Larocca LM, Gaidano G, Hohaus S, Carlo-Stella C, Rossi D.

Blood. 2018 May 31;131(22):2413-2425. doi: 10.1182/blood-2017-11-812073. Epub 2018 Feb 15.

39.

Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines.

Restelli V, Lupi M, Vagni M, Chilà R, Bertoni F, Damia G, Carrassa L.

Target Oncol. 2018 Apr;13(2):235-245. doi: 10.1007/s11523-018-0553-6.

PMID:
29441438
40.

IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas.

Bandini C, Pupuleku A, Spaccarotella E, Pellegrino E, Wang R, Vitale N, Duval C, Cantarella D, Rinaldi A, Provero P, Di Cunto F, Medico E, Bertoni F, Inghirami G, Piva R.

Cancers (Basel). 2018 Jan 18;10(1). pii: E21. doi: 10.3390/cancers10010021.

41.

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, Civenni G, Catapano CV, Sgrignani J, Cavalli A, D'Antuono R, Asara JM, Morandi A, Chiarugi P, Crotti S, Agostini M, Montopoli M, Masgras I, Rasola A, Garcia-Escudero R, Delaleu N, Rinaldi A, Bertoni F, Bono J, Carracedo A, Alimonti A.

Nat Genet. 2018 Feb;50(2):219-228. doi: 10.1038/s41588-017-0026-3. Epub 2018 Jan 15. Erratum in: Nat Genet. 2018 Sep;50(9):1343.

42.

BET Proteins as Targets for Anticancer Treatment.

Stathis A, Bertoni F.

Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20. Review.

43.

ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration.

Puddinu V, Casella S, Radice E, Thelen S, Dirnhofer S, Bertoni F, Thelen M.

Oncotarget. 2017 Jun 29;8(49):85068-85084. doi: 10.18632/oncotarget.18844. eCollection 2017 Oct 17.

44.

Quality of Life After Prostate Cancer Diagnosis: Data from the Pros-IT CNR.

Gacci M, Noale M, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Graziotti P, Magrini SM, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Russi E, Tubaro A, Zagonel V, Crepaldi G, Maggi S; Pros-IT CNR study group.

Eur Urol Focus. 2017 Oct;3(4-5):321-324. doi: 10.1016/j.euf.2017.10.009. Epub 2017 Nov 13.

PMID:
29146557
45.

Application of chitosan in removal of molybdate ions from contaminated water and groundwater.

Bertoni FA, González JC, García SI, Sala LF, Bellú SE.

Carbohydr Polym. 2018 Jan 15;180:55-62. doi: 10.1016/j.carbpol.2017.10.027. Epub 2017 Oct 6.

PMID:
29103521
46.

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.

Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F.

Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24.

47.

TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.

Gaudio E, Paduano F, Pinton S, D'Agostino S, Rocca R, Costa G, Ngankeu A, Aqeilan RI, Croce CM, Bertoni F, Alcaro S, Trapasso F.

Br J Haematol. 2018 Nov;183(3):509-512. doi: 10.1111/bjh.14989. Epub 2017 Oct 19. No abstract available.

PMID:
29048125
48.

Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer. A phase II-III trial.

Ghi MG, Paccagnella A, Ferrari D, Foa P, Alterio D, Codecà C, Nolè F, Verri E, Orecchia R, Morelli F, Parisi S, Mastromauro C, Mione CA, Rossetto C, Polsinelli M, Koussis H, Loreggian L, Bonetti A, Campostrini F, Azzarello G, D'Ambrosio C, Bertoni F, Casanova C, Emiliani E, Guaraldi M, Bunkheila F, Bidoli P, Niespolo RM, Gava A, Massa E, Frattegiani A, Valduga F, Pieri G, Cipani T, Da Corte D, Chiappa F, Rulli E; GSTTC (Gruppo di Studio Tumori della Testa e del Collo) Italian Study Group.

Ann Oncol. 2017 Sep 1;28(9):2206-2212. doi: 10.1093/annonc/mdx299.

PMID:
28911070
49.

Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors.

Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, Bielski CM, Kryukov GV, Cascione L, Napoli S, Enchev RI, Mutch DG, Carney ME, Berchuck A, Winterhoff BJN, Broaddus RR, Schraml P, Moch H, Bertoni F, Catapano CV, Peter M, Carr SA, Garraway LA, Wild PJ, Theurillat JP.

Nat Med. 2017 Sep;23(9):1046-1054. doi: 10.1038/nm.4372. Epub 2017 Aug 14.

50.

Let's give BACH2 a breath of fresh air.

Bertoni F.

Blood. 2017 Aug 10;130(6):696-697. doi: 10.1182/blood-2017-06-790402. No abstract available.

Supplemental Content

Loading ...
Support Center